MedTrace Logo

Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR)

NCT02578511 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2018-02-15

No results posted yet for this study

Summary

In this phase I study, escalating doses of IXAZOMIB will be combined with the POMP/D regimen.

Conditions

  • Acute Lymphoblastic Leukemia in Complete Remission
  • Lymphoblastic Lymphoma in Complete Remission
  • Mixed Phenotype Acute Leukemia in Complete Remission

Interventions

DRUG

Ixazomib

Patients who have been on stable doses of 6 - MP, vincristine, and methotrexate for a minimum of eight weeks and have at least six months remaining of maintenance are eligible to receive Ixazomib, which will be administered on days 1, 8 and 15.

Sponsors & Collaborators

  • Ehab L Atallah

    lead OTHER

Principal Investigators

  • Ehab Atallah, MD · Medical College of Wisconsin

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-29
Primary Completion
2018-02-13
Completion
2018-02-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02578511 on ClinicalTrials.gov